Compare HLX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | PGEN |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1996 | 2013 |
| Metric | HLX | PGEN |
|---|---|---|
| Price | $8.64 | $4.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $11.50 | $8.33 |
| AVG Volume (30 Days) | 1.3M | ★ 4.9M |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $876,561,000.00 | $230,981,000.00 |
| Revenue This Year | $2.05 | $1,115.92 |
| Revenue Next Year | $5.46 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $1.40 |
| 52 Week High | $10.75 | $5.47 |
| Indicator | HLX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 64.27 |
| Support Level | $8.58 | $3.96 |
| Resistance Level | $10.54 | $5.06 |
| Average True Range (ATR) | 0.34 | 0.29 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 14.08 | 94.24 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.